Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of Spero Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $16,137.42. Following the completion of the transaction, the chief financial officer now owns 724,720 shares in the company, valued at approximately $565,281.60. The trade was a 2.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Spero Therapeutics Trading Up 16.4 %

Spero Therapeutics stock opened at $0.88 on Thursday. The stock has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.19. Spero Therapeutics, Inc. has a 12 month low of $0.74 and a 12 month high of $1.89. The company has a market capitalization of $47.81 million, a PE ratio of 12.53 and a beta of 0.61.

Analyst Ratings Changes

Several analysts recently weighed in on SPRO shares. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research note on Thursday, January 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a report on Friday, December 20th. Finally, TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.